Said Chaaban, MD
Pulmonary Disease · Lexington, KYNPI 1619265592
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $336 of the $397 with a category attached, or 84.7%. 5 manufacturers reported payments, led by Boehringer Ingelheim at 32.9% of the total. That places this record below the midpoint for pulmonary disease clinicians in KY, where the typical reported total is $4,124.
Across 5 payments — averaging $79.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$131
- Intuitive Surgical$120
- United Therapeutics Corporation$86
- Genentech USA, Inc.$48
- Merck$13
Across 8 payments — averaging $5937.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$31K
- Roche Products Limited$16K
- Boehringer Ingelheim International GmbH$847
- Boehringer Ingelheim Limited$196
What the payments were for
- Food & beverage$33685%
- Education$6115%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 1 | $131 |
| Intuitive Surgical | 1 | $120 |
| United Therapeutics Corporation | 1 | $86 |
| Genentech USA, Inc. | 1 | $48 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OFEV$131
- Da Vinci Surgical System$120
How this compares
$397 in reported general payments places this provider in the 15th percentile of 226 pulmonary disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pirfenidone | 12 | $10,453 |
| Advair HfaFluticasone Propion/Salmeterol | 11 | $7,400 |
| SymbicortBudesonide/Formoterol Fumarate | 19 | $5,880 |
| Prednisone | 20 | $135 |
| Montelukast Sodium | 16 | $39 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Lexington
- Dennis DohertyLexington$103K
- Ashish MaskeyLexington$94K
- Girish NairLexington$86K
- John ThompsonLexington$77K
- Anthony GerberLexington$20K
- Eliseo Colon-CarrerasLexington$17K
- Christopher MeenachLexington$15K
- Theresa CaseLexington$14K
- John McConnellLouisville$864K
- Erica GregonisRichmond$390K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.